pET-DEST42 Gateway™ Vector
A destination vector for high-level, inducible expression in *E. coli*
Catalog no. 12276-010

Rev. Date: 18 June 2010
Manual part no. 25-0519

MAN0000280
# Table of Contents

Important Information ........................................................................................................iv  
Accessory Products ........................................................................................................v  

**Methods** .......................................................................................................................... 1  
Overview ............................................................................................................................ 1  
Using pET-DEST42 ............................................................................................................. 3  
BL21 *E. coli* Strains ........................................................................................................... 6  
Expression and Analysis ..................................................................................................... 7  

**Appendix** .......................................................................................................................... 9  
Map and Features of pET-DEST42 ..................................................................................... 9  
Technical Service ................................................................................................................ 11  
Purchaser Notification ......................................................................................................... 13  
References ............................................................................................................................ 15
### Important Information

**Shipping and Storage**

pET-DEST42 is shipped at room temperature. Upon receipt, store at -20°C. Product is guaranteed for six months from date of shipment when stored properly.

**Contents**

6 μg pET-DEST42 supplied at a concentration of 150 ng/μl in TE, pH 8.0
Accessory Products

Additional Products

Additional products that may be used with pET-DEST42 are available from Invitrogen. Ordering information is provided below.

<table>
<thead>
<tr>
<th>Product</th>
<th>Amount</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gateway™ LR Clonase™ Enzyme Mix</td>
<td>20 reactions</td>
<td>11791-019</td>
</tr>
<tr>
<td>One Shot® TOP10 Chemically Competent Cells</td>
<td>10 reactions</td>
<td>C4040-10</td>
</tr>
<tr>
<td></td>
<td>20 reactions</td>
<td>C4040-03</td>
</tr>
<tr>
<td>One Shot® TOP10 Electrocompetent Cells</td>
<td>10 reactions</td>
<td>C4040-50</td>
</tr>
<tr>
<td></td>
<td>20 reactions</td>
<td>C4040-52</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>5 g</td>
<td>Q100-16</td>
</tr>
<tr>
<td>Carbenicillin</td>
<td>5 g</td>
<td>10177-012</td>
</tr>
<tr>
<td>IPTG (isopropylthio-β-galactoside)</td>
<td>1 g</td>
<td>15529-019</td>
</tr>
</tbody>
</table>

Detection of Recombinant Proteins

Expression of your recombinant fusion protein can be detected using an antibody to the appropriate epitope. Horseradish peroxidase (HRP) or alkaline phosphatase (AP)-conjugated antibodies allow one-step detection using colorimetric or chemiluminescent detection methods. The amount of antibody supplied is sufficient for 25 Western blots.

<table>
<thead>
<tr>
<th>Product</th>
<th>Epitope</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-V5 Antibody</td>
<td>Detects 14 amino acid epitope derived from the P and V proteins of the paramyxovirus, SV5 (Southern et al., 1991)</td>
<td>R960-25</td>
</tr>
<tr>
<td>Anti-V5-HRP Antibody</td>
<td></td>
<td>R961-25</td>
</tr>
<tr>
<td>Anti-V5-AP Antibody</td>
<td></td>
<td>R962-25</td>
</tr>
<tr>
<td>Anti-His (C-term) Antibody</td>
<td>Detects the C-terminal polyhistidine (6xHis) tag, requires the free carboxyl group for detection (Lindner et al., 1997)</td>
<td>R930-25</td>
</tr>
<tr>
<td>Anti-His(C-term)-HRP Antibody</td>
<td></td>
<td>R931-25</td>
</tr>
<tr>
<td>Anti-His(C-term)-AP Antibody</td>
<td></td>
<td>R932-25</td>
</tr>
<tr>
<td></td>
<td>Detects 14 amino acid epitope derived from the P and V proteins of the paramyxovirus, SV5 (Southern et al., 1991)</td>
<td>R960-25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R961-25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R962-25</td>
</tr>
<tr>
<td></td>
<td>Detects the C-terminal polyhistidine (6xHis) tag, requires the free carboxyl group for detection (Lindner et al., 1997)</td>
<td>R930-25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R931-25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R932-25</td>
</tr>
</tbody>
</table>

continued on next page
Accessory Products, continued

**Purification of Recombinant Fusion Protein**

If your gene of interest is in frame with the C-terminal peptide containing the V5 epitope and the polyhistidine (6xHis) tag, you may use Immobilized Metal Affinity Chromatography (IMAC) to purify your recombinant fusion protein. The ProBond™ Purification System or bulk ProBond™ resin are available separately from Invitrogen. See the table below for ordering information.

<table>
<thead>
<tr>
<th>Product</th>
<th>Quantity</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProBond™ Nickel-chelating Resin</td>
<td>50 ml</td>
<td>R801-01</td>
</tr>
<tr>
<td></td>
<td>150 ml</td>
<td>R801-15</td>
</tr>
<tr>
<td>ProBond™ Purification System</td>
<td>6 purifications</td>
<td>K850-01</td>
</tr>
<tr>
<td>ProBond™ Purification System with Anti-His(C-term)-HRP Antibody</td>
<td>1 kit</td>
<td>K853-01</td>
</tr>
<tr>
<td>ProBond™ Purification System with Anti-V5-HRP Antibody</td>
<td>1 kit</td>
<td>K854-01</td>
</tr>
<tr>
<td>Purification Columns</td>
<td>50</td>
<td>R640-50</td>
</tr>
<tr>
<td>(10 ml polypropylene columns)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Methods

### Overview

**Description**

pET-DEST42 is a 7.4 kb vector adapted for use with the Gateway™ Technology. It is designed to allow high-level, inducible expression of recombinant fusion proteins in *E. coli* using the pET system.

### The pET Expression System

The pET system was originally developed by Studier and colleagues and takes advantage of the high activity and specificity of the bacteriophage T7 RNA polymerase to allow regulated expression of heterologous genes in *E. coli* from the T7 promoter (Rosenberg *et al.*, 1987; Studier and Moffatt, 1986; Studier *et al.*, 1990). For more information about T7-regulated expression, see the next page.

### Features

pET-DEST42 contains the following elements:

- **T7lac** promoter for high-level, IPTG-inducible expression of the gene of interest in *E. coli* (see next page for more information)

- Two recombination sites, *attR*1 and *attR*2, downstream of the T7 promoter for recombinational cloning of the gene of interest from an entry clone

- Chloramphenicol resistance gene located between the two *attR* sites for counterselection

- The *ccdB* gene located between the two *attR* sites for negative selection

- V5 epitope and 6xHis tag for detection and purification (optional)

- Ampicillin resistance gene for selection in *E. coli*

- pBR322 origin for low-copy replication and maintenance of the plasmid in *E. coli*

- *lacI* gene encoding the lac repressor to reduce basal transcription from the T7lac promoter

For a map of pET-DEST42, see page 9.
The Gateway™ Technology

Gateway™ is a universal cloning technology that takes advantage of the site-specific recombination properties of bacteriophage lambda (Landy, 1989) to provide a rapid and highly efficient way to move your gene of interest into multiple vector systems. To express your gene of interest using Gateway™ cloning technology, simply:

1. Clone your gene of interest into a Gateway™ entry vector to create an entry clone.
2. Generate an expression clone by performing an LR recombination reaction between the entry clone and a Gateway™ destination vector (e.g. pET-DEST42).
3. Transform your expression clone into a BL21 strain of choice. Induce expression of your protein with IPTG.

For more information on the Gateway™ System, refer to the Gateway™ Technology Manual. This manual is available for downloading from our Web site (www.invitrogen.com) or by contacting Technical Service (page 11).

T7-Regulated Expression

pET-DEST42 uses elements from bacteriophage T7 to control expression of heterologous genes in E. coli. In the vector, expression of the gene of interest is controlled by a strong bacteriophage T7 promoter that has been modified to contain a lac operator sequence (see below). In bacteriophage T7, the T7 promoter drives expression of gene 10 (10). T7 RNA polymerase specifically recognizes this promoter. To express the gene of interest, it is necessary to deliver T7 RNA polymerase to the cells by inducing expression of the polymerase or infecting the cell with phage expressing the polymerase.

T7/lac Promoter

pET-DEST42 has been designed to contain a T7lac promoter to drive expression of the gene of interest. The T7lac promoter consists of a lac operator sequence placed downstream of the T7 promoter. The lac operator serves as a binding site for the lac repressor (encoded by the lacI gene) and functions to further repress T7 RNA polymerase-induced basal transcription of the gene of interest in BL21 strains.
Using pET-DEST42

Important

The pET-DEST42 vector is supplied as a supercoiled plasmid. Although Invitrogen has previously recommended using a linearized destination vector for more efficient recombination, further testing has found that linearization of this vector is NOT required to obtain optimal results for any downstream application.

Propagating pET-DEST42

If you wish to propagate and maintain pET-DEST42, we recommend using Library Efficiency® DB3.1™ Competent Cells (Catalog no. 11782-018) from Invitrogen for transformation. The DB3.1™ E. coli strain is resistant to CcdB effects and can support the propagation of plasmids containing the ccdB gene.

DO NOT use general E. coli cloning strains including TOP10 or DH5α for propagation and maintenance as these strains are sensitive to CcdB effects.

Entry Clone

To recombine your gene of interest into pET-DEST42, you should have an entry clone containing your gene of interest. For your convenience, Invitrogen offers the pENTR Directional TOPO® Cloning Kit (Catalog no. K2400-20) for 5-minute cloning of your gene of interest into an entry vector. For more information, refer to our Web site (www.invitrogen.com) or contact Technical Service (page 11).

For detailed information on constructing an entry clone, refer to the specific entry vector manual. For detailed information on performing the LR recombination reaction, refer to the Gateway™ Technology Manual.

continued on next page
Using pET-DEST42, continued

Points to Consider Before Recombining

- Your insert should contain a ribosome binding site [AGGAG(A/G)] approximately 9-10 base pairs upstream of the ATG initiation codon (Gold, 1988; Miller, 1992). This will ensure the optimal spacing for proper initiation of translation.

- If you wish to include the V5 epitope and 6xHis tag, your gene in the entry clone should not contain a stop codon. The gene should also be designed to be in frame with the C-terminal epitope tag after recombination. Refer to the Recombination Region on the next page.

- If you DO NOT wish to include the V5 epitope and 6xHis tag, your gene should contain a stop codon in the entry clone.

Recombining Your Gene of Interest

Each entry clone contains attL sites flanking the gene of interest. Genes in an entry clone are transferred to the destination vector backbone by mixing the DNAs with the Gateway™ LR Clonase™ enzyme mix. The resulting recombination reaction is then transformed into E. coli and the expression clone selected. Recombination between the attR sites on the destination vector and the attL sites on the entry clone replaces the ccdB gene and the chloramphenicol (CmR) gene with the gene of interest and results in the formation of attB sites in the expression clone.

Follow the instructions in the Gateway™ Technology Manual to set up the LR Clonase™ reaction, transform a recA endA E. coli strain (e.g. TOP10 or DH5), and select for the expression clone.

Confirming the Expression Clone

The ccdB gene mutates at a very low frequency, resulting in a very low number of false positives. True expression clones will be ampicillin-resistant and chloramphenicol-sensitive. Transformants containing a plasmid with a mutated ccdB gene will be both ampicillin- and chloramphenicol-resistant. To check your putative expression clone, test for growth on LB plates containing 30 μg/ml chloramphenicol. A true expression clone will not grow in the presence of chloramphenicol.

continued on next page
Using pET-DEST42, continued

Recombination Region

The recombination region of the expression clone resulting from pET-DEST42 × entry clone is shown below.

Features of the Recombination Region:

- Shaded regions correspond to those DNA sequences transferred from the entry clone into pET-DEST42 by recombination. Non-shaded regions are derived from the pET-DEST42 vector.
- The underlined nucleotides flanking the shaded region correspond to bases 409 and 2092, respectively, of the pET-DEST42 vector sequence.

The Next Step

Once you have generated your expression clone, you will need to transform it into a BL21 E. coli strain for expression studies. Proceed to the next section for guidelines on choosing a BL21 host strain.
**Introduction**

This section provides information on strains available from Invitrogen that are specifically designed for use with T7 promoter-based expression systems. **Note:** Other BL21 strains are suitable.

---

**Recommended Strains**

See the table below for recommended strains and their benefits. For more information on these strains and other BL21 strains available from Invitrogen, refer to our Web site (www.invitrogen.com) or contact Technical Service (page 11).

<table>
<thead>
<tr>
<th>Product</th>
<th>Benefit</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL21 Star™ (DE3) One Shot® Chemically Competent <em>E. coli</em></td>
<td>Mutation in RNaseE improves stability of mRNA transcripts and increases protein yields.</td>
<td>C6010-03</td>
</tr>
<tr>
<td>BL21-AI™ One Shot® Chemically Competent <em>E. coli</em></td>
<td>T7 RNA polymerase under the control of <em>araBAD</em> promoter for inducible expression and low basal levels. Especially useful for expression of toxic genes.</td>
<td>C6070-03</td>
</tr>
</tbody>
</table>
Expression and Analysis

Introduction

Once you have selected your E. coli host strain, you are ready to test for expression of your gene. This section provides general guidelines for expressing and analyzing your protein of interest. For detailed information on transforming your BL21 strain, inducing expression with IPTG, and analyzing samples, refer to your specific BL21 E. coli strain manual. If you are using a BL21 strain from Invitrogen, the manuals are available for downloading from our Web site or by contacting Technical Service (page 11).

Basic Strategy

The basic steps needed to induce expression of your gene in a BL21 E. coli strain are outlined below.

1. Isolate plasmid DNA using standard procedures and transform your construct into BL21 cells.

2. Grow the transformants and induce expression with IPTG over several hours. Take several time points to determine the optimal time of expression.

Plasmid Preparation

You may prepare plasmid DNA using your method of choice. We recommend using the S.N.A.P.™ MidiPrep Kit (Catalog no. K1910-01) for isolation of pure plasmid DNA. Note that since you are purifying a low-copy number plasmid, you may need to increase the amount of bacterial culture that you use to prepare your plasmid construct.

Choosing a Selection Agent

For most purposes, ampicillin works well for selection of transformants and expression experiments. However, if you find that your expression level is low, you may want to use carbenicillin instead. The resistance gene for ampicillin encodes a protein called β-lactamase. This protein is secreted into the medium where it hydrolyzes ampicillin, inactivating the antibiotic. Since β-lactamase is catalytic, ampicillin is rapidly removed from the medium, resulting in non-selective conditions. If your plasmid is unstable, this may result in the loss of plasmid and low expression levels.

continued on next page
Using Carbenicillin

Carbenicillin is generally more stable than ampicillin, and studies have shown that using carbenicillin in place of ampicillin may help to increase expression levels by preventing loss of the pET-DEST42 expression plasmid. If you wish to use carbenicillin, perform your transformation and expression experiments in LB containing 50 μg/ml carbenicillin.

Note: If your gene of interest is highly toxic, increasing the concentration of carbenicillin used from 50 μg/ml to 200 μg/ml may help to increase expression levels.

Detection of Recombinant Fusion Proteins

To detect expression of your recombinant fusion protein by Western blot analysis, you may use antibodies against the appropriate epitope (see page v for ordering information) or an antibody to your protein of interest. In addition, the Positope™ Control Protein (Catalog no. R900-50) is available from Invitrogen for use as a positive control for detection of fusion proteins containing a V5 epitope or a polyhistidine (6xHis) tag. For more information, refer to our Web site (www.invitrogen.com) or contact Technical Service (page 11).

Note

The C-terminal peptide containing the V5 epitope and the polyhistidine tag will add approximately 4 kDa to your protein.

Purification of Recombinant Fusion Proteins

The presence of the C-terminal polyhistidine (6xHis) tag in your recombinant fusion protein allows use of a metal-chelating resin such as ProBond™ to purify your fusion protein. The ProBond™ Purification System and bulk ProBond™ resin are available from Invitrogen (see page vi for ordering information). Invitrogen also offers Ni-NTA Agarose (Catalog no. R901-01) for purification of proteins containing a polyhistidine (6xHis) tag. Note: Other metal-chelating resins and purification methods are suitable.
Appendix

Map and Features of pET-DEST42

The map below shows the elements of pET-DEST42. DNA from the entry clone replaces the region between bases 409 and 2092. The complete sequence of pET-DEST42 is available from our Web site (www.invitrogen.com) or by contacting Technical Service (page 11).

Comments for pET-DEST42
7440 nucleotides

T7 promoter: bases 318-334
lac operator (lacO): bases 337-361
attR1 recombination site: bases 402-526
Chloramphenicol resistance gene: bases 635-1294
ccdB gene: bases 1636-1941
attR2 recombination site: bases 1982-2106
V5 epitope: bases 2126-2167
Polyhistidine (6xHis) region: bases 2177-2194
T7 transcription termination region: bases 2209-2337
bla promoter: bases 2638-2736
Ampicillin (bla) resistance gene (ORF): bases 2737-3597
pBR322 origin: bases 3742-4415
ROP ORF: bases 4786-4977 (complementary strand)
lacI ORF: bases 6289-7380 (complementary strand)

continued on next page
Map and Features of pET-DEST42, continued

Features of pET-DEST42

pET-DEST42 (7440 bp) contains the following elements. All features have been functionally tested.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>T7 promoter</td>
<td>Allows high-level, IPTG-inducible expression of your recombinant protein in <em>E. coli</em> strains expressing the T7 RNA polymerase</td>
</tr>
<tr>
<td><em>lac</em> operator (<em>lacO</em>)</td>
<td>Binding site for <em>lac</em> repressor that serves to reduce basal expression of the recombinant protein</td>
</tr>
<tr>
<td><em>att</em>R1 and <em>att</em>R2 sites</td>
<td>Allows recombinational cloning of the gene of interest from an entry clone</td>
</tr>
<tr>
<td>Chloramphenicol resistance gene</td>
<td>Allows counterselection of expression clones</td>
</tr>
<tr>
<td><em>ccdB</em> gene</td>
<td>Allows negative selection of expression clones</td>
</tr>
<tr>
<td>V5 epitope</td>
<td>Allows detection of the recombinant protein by the Anti-V5 antibodies (Southern <em>et al.</em>, 1991)</td>
</tr>
<tr>
<td>C-terminal polyhistidine tag</td>
<td>Allows purification of the recombinant protein on metal-chelating resin such as ProBond™ and allows detection of the recombinant protein by the Anti-His (C-term) antibodies (Lindner <em>et al.</em>, 1997)</td>
</tr>
<tr>
<td>T7 transcription termination region</td>
<td>Sequence from bacteriophage T7 which allows efficient transcription termination.</td>
</tr>
<tr>
<td><em>bla</em> promoter</td>
<td>Allows expression of the ampicillin resistance gene</td>
</tr>
<tr>
<td>Ampicillin resistance gene</td>
<td>Allows selection of the plasmid in <em>E. coli</em></td>
</tr>
<tr>
<td>pBR322 origin</td>
<td>Allows replication and maintenance in <em>E. coli</em></td>
</tr>
<tr>
<td><em>lacI</em> ORF</td>
<td>Encodes <em>lac</em> repressor which binds to the T7<em>lac</em> promoter to block basal transcription of the gene of interest. Also binds the <em>lac</em>UV5 promoter in BL21 strains containing the λDE3 lysogen to repress transcription of T7 RNA polymerase</td>
</tr>
</tbody>
</table>
Visit the Invitrogen Web site at www.invitrogen.com for:

- Technical resources, including manuals, vector maps and sequences, application notes, SDSs, FAQs, formulations, citations, handbooks, etc.
- Complete technical service contact information
- Access to the Invitrogen Online Catalog
- Additional product information and special offers

For more information or technical assistance, call, write, fax, or email. Additional international offices are listed on our Web page (www.invitrogen.com).

Corporate Headquarters:
5791 Van Allen Way
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail: tech_service@invitrogen.com

Japanese Headquarters:
LOOP-X Bldg. 6F
3-9-15, Kaigan Minato-ku, Tokyo 108-0022
Tel: 81 3 5730 6509
Fax: 81 3 5730 6519
E-mail: jpinfo@invitrogen.com

European Headquarters:
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK
Tel: +44 (0) 141 814 6100
Tech Fax: +44 (0) 141 814 6117
E-mail: eurotech@invitrogen.com

Safety Data Sheets (SDSs) are available at www.invitrogen.com/sds

The Certificate of Analysis provides detailed quality control and product qualification information for each product. Certificates of Analysis are available on our website. Go to www.invitrogen.com/support and search for the Certificate of Analysis by product lot number, which is printed on the box.

continued on next page
Invitrogen (a part of Life Technologies Corporation) is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, contact our Technical Support Representatives.

All Invitrogen products are warranted to perform according to specifications stated on the certificate of analysis. The Company will replace, free of charge, any product that does not meet those specifications. This warranty limits the Company’s liability to only the price of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. The Company reserves the right to select the method(s) used to analyze a product unless the Company agrees to a specified method in writing prior to acceptance of the order.

Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore the Company makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, report it to our Technical Support Representatives.

Life Technologies Corporation shall have no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.
Purchaser Notification

Introduction

pET-DEST42 is covered under the licenses detailed below.

Limited Use Label License
No. 19: Gateway® Cloning Products

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for profit entity). The purchase of this product does not convey a license under any method claims in the foregoing patents or patent applications, or to use this product with any recombination sites other than those purchased from Life Technologies Corporation or its authorized distributor. The right to use methods claimed in the foregoing patents or patent applications with this product for research purposes only can only be acquired by the use of Clonase™ purchased from Life Technologies Corporation or its authorized distributors. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the employment of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Notwithstanding the preceding, any buyer who is employed in an academic or government institution may transfer materials made with this product to a third party who has a license from Life Technologies under the patents identified above to distribute such materials. Transfer of such materials and/or information to collaborators does not convey rights to practice any methods claimed in the foregoing patents or patent applications. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Life Technologies Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that none of (i) this product, (ii) any of its components, or (iii) a method claim of the foregoing patents, was used in the manufacture of such product. Life Technologies Corporation will not assert a claim against the buyer of infringement of the above patents based upon the use of this product to manufacture a protein for sale, provided that no method claim in the above patents was used in the manufacture of such protein. If the purchaser is not willing to accept the limitations of this limited use statement, Life Technologies is willing to accept return of the product with a full refund. For information on purchasing a license to use this product for purposes other than those permitted above, contact Licensing Department, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200.

continued on next page
Purchaser Notification, continued

Limited Use Label
License No. 22:
Vectors and Clones
Encoding Histidine
Hexamer

This product is licensed under U.S. Patent Nos. 5,284,933 and 5,310,663 and foreign equivalents from Hoffmann-LaRoche, Inc., Nutley, NJ and/or Hoffmann-LaRoche Ltd., Basel, Switzerland and is provided only for use in research. Information about licenses for commercial use is available from QIAGEN GmbH, Max-Volmer-Str. 4, D-40724 Hilden, Germany.

Limited Use Label
License No. 30: T7 Expression System

The composition and/or use of this product may be claimed in U.S. Patent No. 5,693,489 licensed to Life Technologies Corporation by Brookhaven Science Associates, LLC. The T7 expression system is based on technology developed at Brookhaven National Laboratory under contract with the U.S. Department of Energy, and is the subject of patents and patent applications assigned to Brookhaven Science Associates, LLC (BSA). By provisions of the Distribution License Agreement granted to Life Technologies covering said patents and patent applications, Life Technologies grants you a non-exclusive sub-license under patents assigned to BSA for the use of this technology, including the enclosed materials, based upon the following conditions: 1 – these materials are to be used for non-commercial research purposes only. A separate license under patents owned by BSA is required for any commercial use, including the use of these materials for research purposes or production purposes by any commercial entity. Information about commercial license may be obtained from The Office of Technology Transfer, Brookhaven National Laboratory, Bldg. 475D, P.O. Box 5000, Upton, New York 11973-5000. Phone (516) 344-7134. 2 - No materials that contain the cloned copy of the T7 gene 1, the gene for T7 RNA polymerase, may be distributed further to third parties outside of your laboratory, unless the recipient receives a copy of this sub-license and agrees to be bound by its terms. This limitation applies to strains BL21(DE3), BL21(DE3)pLysS and BL21(DE3)pLysE, C6E6, BL21-SI Competent Cells and any derivatives that are made of them. You may refuse this sub-license by returning this product unused in which case Life Technologies accept return of the product with a full refund. By keeping or using this product, you agree to be bound by the terms of this license.

Limited Use Label
License No. 54: ULB ccdB Selection Technology

This product is the subject of one or more of U.S. Patent Numbers 5,910,438, 6,180,407, and 7,176,029 and corresponding foreign patents and is sold under license from the Université Libre de Bruxelles for research purposes only. ccdB selection technology is described in Bernard et al., "Positive Selection Vectors Using the F Plasmid ccdB Killer Gene" Gene 148 (1994) 71-74. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). For licensing information for use in other than research, please contact: Out Licensing, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, California 92008; Phone (760) 603-7200 or e-mail.
References


©2010 Life Technologies Corporation. All rights reserved.
For research use only. Not intended for any animal or human therapeutic or diagnostic use. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.
Notes